Allergan PLC's pact with the Saint Regis Mohawk Tribe, intended to help Allergan secure patent protection for its dry eye blockbuster Restasis (cyclosporine), has done what many companies are hoping not to do – caught the attention of legislators in Washington, D.C.
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
More from Legal & IP
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.